Efficacy and safety of first‐line treatments for patients with advanced anaplastic lymphoma kinase mutated, non–small cell cancer: A systematic review and network meta‐analysis
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34664
Abstract: This study compares the safety and efficacy of first‐line treatments for anaplastic lymphoma kinase (ALK)‐mutated non–small cell lung cancer (NSCLC). read more here.
Keywords: lymphoma kinase; anaplastic lymphoma; first line; mutated non ... See more keywords
Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.1989
Abstract: Crizotinib and alectinib are anaplastic lymphoma kinase (ALK)‐inhibitors indicated for the treatment of ALK‐positive metastatic non‐small cell lung cancer (NSCLC). At the currently used fixed doses, interindividual variability in exposure is high. The aim of… read more here.
Keywords: lymphoma kinase; anaplastic lymphoma; crizotinib; crizotinib alectinib ... See more keywords
Structural basis for drug resistance mechanisms against anaplastic lymphoma kinase
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cellular Biochemistry"
DOI: 10.1002/jcb.27437
Abstract: Drug resistance to anaplastic lymphoma kinase (ALK) inhibitors (crizotinib and ceritinib) is caused by mutation in the region encoding kinase domain of ALK. Compounds with potential ability to inhibit all strains of ALK are a… read more here.
Keywords: drug; lymphoma kinase; drug resistance; anaplastic lymphoma ... See more keywords
Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.2056
Abstract: Lorlatinib is a third‐generation, brain‐penetrant anaplastic lymphoma kinase (ALK) and c‐ros oncogene 1 (ROS1) tyrosine kinase inhibitor (TKI) with robust intracranial activity in patients with ALK‐ or ROS1‐positive non‐small cell lung cancer (NSCLC). Data from… read more here.
Keywords: lymphoma kinase; anaplastic lymphoma; kinase alk; kinase ... See more keywords
Density Functional Theory and Molecular Simulation Studies for Prioritizing Anaplastic Lymphoma Kinase Inhibitors
Sign Up to like & getrecommendations! Published in 2019 at "Applied Biochemistry and Biotechnology"
DOI: 10.1007/s12010-019-03156-1
Abstract: Targeting anaplastic lymphoma kinase (ALK) is one of the important treatment strategies for the treatment of non-small cell lung cancer (NSCLC). In the present perspective, multidimensional approaches were used for the identification of ALK inhibitors.… read more here.
Keywords: lymphoma kinase; functional theory; density functional; anaplastic lymphoma ... See more keywords
Recurrent hyperglycemic hyperosmolar state after re-administration of dose-reduced ceritinib, an anaplastic lymphoma kinase inhibitor
Sign Up to like & getrecommendations! Published in 2020 at "Diabetology International"
DOI: 10.1007/s13340-020-00442-w
Abstract: Ceritinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor with clinical activity in crizotinib-resistant ALK-positive non-small cell lung cancer and in treatment-naïve ALK-positive disease. Hyperglycemia is a known adverse event, but the mechanism by which… read more here.
Keywords: lymphoma kinase; hyperosmolar state; administration; anaplastic lymphoma ... See more keywords
Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
Sign Up to like & getrecommendations! Published in 2018 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2018.03.071
Abstract: Anaplastic lymphoma kinase (ALK) activation has been associated with many types of human cancer. Significant efforts have been devoted to the development of ALK inhibitors to antagonize the kinase activity of ALK. Four ALK inhibitors… read more here.
Keywords: lymphoma kinase; lymphoma; alk; anaplastic lymphoma ... See more keywords
Anaplastic lymphoma kinase inhibitor therapy in the treatment of inflammatory myofibroblastic tumors in pediatric patients: Case reports and literature review.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of pediatric surgery"
DOI: 10.1016/j.jpedsurg.2021.02.004
Abstract: BACKGROUND Inflammatory myofibroblastic tumors (IMTs) are a rare subtype of inflammatory pseudotumor frequently associated with rearrangement of the anaplastic lymphoma kinase (ALK) gene. Their treatment has historically relied on at-times challenging and morbid surgical excision.… read more here.
Keywords: lymphoma kinase; myofibroblastic tumors; literature review; anaplastic lymphoma ... See more keywords
Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase
Sign Up to like & getrecommendations! Published in 2022 at "ACS Omega"
DOI: 10.1021/acsomega.2c00507
Abstract: The anaplastic lymphoma kinase (ALK) is abnormally expressed and hyperactivated in a number of tumors and represents an ideal therapeutic target. Despite excellent clinical responses to ALK inhibition, drug resistance still represents an issue and… read more here.
Keywords: lymphoma kinase; lymphoma; discovery novel; anaplastic lymphoma ... See more keywords
Structure and energy based quantitative missense variant effect analysis provides insights into drug resistance mechanisms of anaplastic lymphoma kinase mutations
Sign Up to like & getrecommendations! Published in 2018 at "Scientific Reports"
DOI: 10.1038/s41598-018-28752-9
Abstract: Anaplastic lymphoma kinase (ALK) is considered as a validated molecular target in multiple malignancies, such as non-small cell lung cancer (NSCLC). However, the effectiveness of molecularly targeted therapies using ALK inhibitors is almost universally limited… read more here.
Keywords: drug resistance; lymphoma kinase; alk; anaplastic lymphoma ... See more keywords
EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Japanese journal of clinical oncology"
DOI: 10.1093/jjco/hyaa156
Abstract: Ovarian cancer is prone to recurrence and chemotherapy resistance. Ovarian tumours of some patients have been positive for anaplastic lymphoma kinase fusion gene expression (ALK+). Preclinical studies indicate that anaplastic lymphoma kinase inhibitor can suppress… read more here.
Keywords: lymphoma kinase; anaplastic lymphoma; ovarian cancer; cancer ... See more keywords